Residency Program Director
Hallie Barr, PharmD, MBA, BCOP
- Pharmacy Manager, Investigational Drug Service
- Investigational Drugs and Research Residency Program Director
Previous Year Residents
Alexis Mann, PharmD, MBAIDS Research Pharmacist - The Ohio State University Wexner Medical Center
Frisca Kang, PharmDOncology Research Pharmacist, Cedars-Sinai, Los Angeles, California
About the PGY1 Pharmacy/PGY2 Investigational Drugs and Research Residency Program
PGY1 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and outcomes to contribute to the development of clinical pharmacists responsible for medication related care of patients with a wide range of conditions, eligible for board certification, and eligible for postgraduate year two (PGY2) pharmacy residency training.
PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.
Residents completing the PGY1 Pharmacy/PGY2 Investigational Drugs and Research residency program at The Ohio State University Wexner Medical Center (OSUWMC) will gain specialized knowledge and skills to operate as an effective and expert practitioner in research pharmacy. Residents will have the opportunity to interact with world-renowned researchers in both oncology and non-oncology areas throughout the medical center. By the end of their PGY-2 program, the resident will have the training required to seek a specialized research pharmacist position in a variety of settings including, but not limited to, hospitals, academia, and industry.
Residents completing the PGY1 Pharmacy/PGY2 Investigational Drugs and Research Residency are eligible to receive a PGY1 Pharmacy Residency certificate and a PGY2 Investigational Drugs and Research Residency certificate.
The Ohio State University Wexner Medical Center (OSUWMC) is a 1,506 bed tertiary care medical center located in Columbus, Ohio. It is a multi-hospital delivery system recognized in 2022 as one of “America’s Best Hospitals” for excellence in 9 specialties by US News and World Report based on quality, outcomes, and reputation.Read More
The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital will be the primary practice site for the Investigational Drugs and Research residency. The James is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer Institute, and is the third largest cancer center in the nation. Opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.
University Hospital (UH)
University Hospital (UH) will serve as an additional site serving patients and research in non-oncologic disease states. UH is our flagship hospital with over 900 beds and is a major referral center for patients throughout Ohio and the Midwest, and is one of the busiest kidney and pancreas transplant centers in the world. UH is also an international center for neuromodulation research and neurological care. In addition, UH is a level 1 trauma center in addition to being the American Burn Associated verified adult burn center for the region.
Key Rotations / Experiences
Rotational experience is designed to provide the resident with broad exposure to pharmacy services and patient populations and is the backbone of the PGY1 Residency experience. The structure of the resident’s rotation schedule will be tailored to each resident.
Please see additional information: https://osupharmacyresidency.com/residency-programs/post-graduate-year-1-programs/health-system/
The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest. The following is a list of the required learning experiences:
- Investigational Drug Service (IDS) Core
- IDS Leadership
- Clinical Trial Office
- Clinical Trial Management Office
- Office of Responsible Research Practices
- Clinical Inpatient
- Clinical Outpatient
- Clinical Treatment Unit
- Research Informatics
- Drug Development Institute
- Institutional Review Board
- IDS Longitudinal
- Clinical or Quality Research Project
- Operational Staffing
Elective offerings may vary according to the interests of the resident.
Hallie Barr, PharmD, MBA, BCOP
Pharmacy Manager, Investigational Drug Service
Kelley Barley, PharmD
Naomi Digiantonio, PharmD, BCPS
Generalist Pharmacist, Clinical Treatment Unit
Emily Harmon, PharmD
Daniel Haas, MS, RPh
Amanda Sabol, PharmD, MPH, BCPS
Jennifer Severing, PharmD, BCPS
Alexis Mann, PharmD, MBA
Jeffrey Patrick, PharmD
Director, Drug Development Institute
Sandra Meadows, MPH, CIP
Program Manager, Educational Programming and Regulatory Support
Office of Responsible Research Practices
Assistant Director, Clinical Trials Office
OSU Comprehensive Cancer Center
Lisa Hafer, MPH, CCRP
Assistant Director-Operations, Clinical Trials Management Organization
Center or Clinical Research Management, College of Medicine
Benefits and Additional Requirements
Application Deadline: January 2, 2024
We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).
Along with your application, we require three letters of recommendation. It is highly recommended that one to two of the letters be from a clinical rotation preceptor within the past six months.
Start Date: June 17, 2024
Annual Salary- PGY1 $49,500/PGY2 $50,500
Vacation Days- 10 days per year
Staffing Requirement- PGY1 = 24 weekends; PGY2 = 20 weekends
Completion of a Major Research Project in each year